Human Health and Disease Affected by Microbiome Dysbiosis

Cristina Mocanu^*
*Correspondence: Cristina Mocanu, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy, Email:

Keywords

Microbiome • Dysbiosis • Gut microbiota • Human health Disease

Introduction

The human body is home to trillions of microorganisms that make up our microbiome. These microorganisms, primarily residing in our gut, form a complex and diverse community that influences numerous aspects of our health. The gut microbiota, in particular, has garnered significant attention due to its essential functions in digestion, nutrient absorption and immune system development. However, disruptions in the delicate balance of this microbial community can lead to dysbiosis, which is characterized by alterations in the composition, diversity and functionality of the microbiome. This article aims to explore the concept of microbiome dysbiosis, examine its causes and discuss its implications for human health and disease.

Several factors can contribute to microbiome dysbiosis. One of the primary culprits is the overuse of antibiotics, which indiscriminately kill both harmful and beneficial bacteria, leading to imbalances in the gut microbiota. Additionally, a diet high in processed foods and low in fiber can negatively impact microbial diversity, as certain beneficial bacteria rely on dietary fibers for their growth and function. Other factors that can disrupt the microbiome include stress, lack of sleep, environmental toxins and certain medical conditions. Beyond the gut, dysbiosis has also been linked to systemic diseases like obesity, type 2 diabetes and cardiovascular disease. Researchers have found that certain microbial imbalances can affect metabolism, leading to weight gain and insulin resistance [1].

Microbiome dysbiosis has been implicated in various health conditions and diseases. One of the most well-known associations is with gastrointestinal disorders, such as Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). In these conditions, dysbiosis is often characterized by a decrease in beneficial bacteria and an overgrowth of harmful microbes, leading to chronic inflammation and intestinal dysfunction. Dysbiosis-induced inflammation can contribute to the development of atherosclerosis and other cardiovascular complications. Furthermore, emerging evidence suggests a potential role of dysbiosis in mental health conditions, such as depression and anxiety, as the gut-brain axis enables bidirectional communication between the gut microbiota and the brain. Microbiome dysbiosis can be caused by a number of things. Unbalances in the gut microbiota are brought about by the misuse of antibiotics, which indiscriminately kill both dangerous and beneficial microorganisms. Additionally, because some helpful bacteria depend on dietary fibres for their growth and function, a diet high in processed foods and low in fibre can harm microbial diversity [2].

Literature Review

Recognizing the significance of a healthy microbiome, researchers are exploring various strategies to restore microbiome balance and alleviate dysbiosis-associated symptoms. Probiotics, which are live microorganisms that confer health benefits when consumed, have gained popularity as a potential tool to promote a healthy gut microbiota. Prebiotics are non-digestible dietary fibers that selectively stimulate the growth and activity of beneficial bacteria. Additionally, Fecal Microbiota Transplantation (FMT), a procedure involving the transfer of fecal material from a healthy donor to a recipient, has shown promise in treating certain conditions associated with dysbiosis, such as recurrent Clostridium difficile infection. The human microbiome and its intricate relationship with our health have become subjects of extensive research. Microbiome dysbiosis, characterized by imbalances in the composition and functionality of the microbiota, can have far-reaching effects on human health and disease. While significant progress has been made in understanding the impact of microbiome dysbiosis on human health, there are still many avenues for exploration and potential implications to consider [3].

The field of precision medicine aims to develop personalized approaches to healthcare by considering an individual's unique genetic makeup, lifestyle, and environmental factors. Integrating microbiome analysis into this framework holds great promise. By understanding an individual's specific microbiome profile, healthcare providers can tailor interventions and treatments to restore microbial balance and optimize health outcomes. As the understanding of the microbiome advances, novel therapeutic strategies targeting dysbiosis may emerge. For example, the development of next-generation probiotics that are specifically designed to address dysbiosis-associated conditions could provide more targeted and effective treatments.

Additionally, the identification and isolation of specific beneficial microbes or their metabolites may lead to the development of microbial-based therapies to restore microbial balance. The early stages of life, particularly infancy and early childhood, are critical periods for microbiome development. Dysbiosis during these formative years can have long-lasting effects on health. Exploring interventions such as promoting breastfeeding, avoiding unnecessary antibiotic use, and implementing dietary and lifestyle interventions to foster a healthy microbiome from an early age may have a significant impact on reducing the risk of dysbiosis-related diseases later in life. Research efforts are underway to identify specific microbiome signatures or biomarkers associated with dysbiosis and various diseases [4].

By establishing these biomarkers, it may be possible to develop non-invasive diagnostic tools to detect dysbiosis early on and monitor treatment effectiveness. This could lead to more targeted and timely interventions, improving patient outcomes. While dysbiosis is often associated with gut-related conditions, researchers are exploring the potential impact of dysbiosis in other parts of the body, such as the skin, oral cavity and respiratory tract. Understanding the role of dysbiosis in these contexts may lead to the development of microbiome-based therapies for conditions like acne, periodontal disease and respiratory disorders [5].

Discussion

As we continue to unravel the complexities of the microbiome and its relationship to human health, personalized approaches to maintaining a healthy microbiome and preventing dysbiosis-related diseases hold great promise. By embracing advancements in precision medicine, developing targeted therapies and identifying biomarkers, we can pave the way for more effective strategies to restore and maintain microbiome balance, ultimately improving overall human health and well-being. The impacts of dysbiosis span beyond the gut, influencing various physiological processes and contributing to the development of conditions ranging from gastrointestinal disorders to metabolic and mental health diseases. Efforts to restore microbiome balance through interventions like probiotics, prebiotics and FMT hold promise for improving health outcomes. As our understanding of the microbiome grows, further research is needed to uncover the complexities of dysbiosis and its potential therapeutic interventions, ultimately paving the way for personalized approaches to maintain a healthy microbiome and prevent associated diseases [6].

Conclusion

The human microbiome and its delicate balance play a fundamental role in maintaining health and preventing disease. Dysbiosis, characterized by disturbances in microbial composition and function, has emerged as a significant factor contributing to various health conditions and diseases. The implications of microbiome dysbiosis reach far beyond the gut, affecting metabolic processes, immune function and even mental health. Recognizing the importance of a healthy microbiome, researchers are exploring innovative interventions to restore microbial balance and improve health outcomes.

Acknowledgement

We thank the anonymous reviewers for their constructive criticisms of the manuscript.

Conflict of Interest

The author declares there is no conflict of interest associated with this manuscript.

References

1. Ostrov, Barbara E. and Daniel Amsterdam. "Immunomodulatory interplay of the microbiome and therapy of rheumatic diseases." Immunol Invest 46 (2017): 769-792.

Google Scholar, Crossref, Indexed at

2. Vyas, Usha and Natarajan Ranganathan. "Probiotics, prebiotics and synbiotics: Gut and beyond." Gastroenterol Res Pract 2012 (2012).

Google Scholar, Crossref, Indexed at

3. Nemet, Ina, Prasenjit Prasad Saha, Nilaksh Gupta and Weifei Zhu, et al. "A cardiovascular disease-linked gut microbial metabolite acts via adrenergic receptors." Cell 180 (2020): 862-877.

Google Scholar, Crossref, Indexed at

4. Doron, Shira and David R. Snydman. "Risk and safety of probiotics." Clin Infect Dis 60 (2015): S129-S134.

Google Scholar, Crossref, Indexed at

5. Zhu, Weifei, Jill C. Gregory, Elin Org and Jennifer A. Buffa, et al. "Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk." Cell 165 (2016): 111-124.

Google Scholar, Crossref, Indexed at

6. Peschel, Thomas, Martin Schönauer, Holger Thiele and Stefan Anker, et al. "Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure." Eur J Heart Fail 5 (2003): 609-614.

Google Scholar, Crossref, Indexed at